Amedisys Inc (NASDAQ:AMED) CFO Scott G. Ginn sold 4,872 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $118.50, for a total value of $577,332.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
AMED traded up $0.44 on Wednesday, reaching $118.04. The company’s stock had a trading volume of 281,027 shares, compared to its average volume of 452,808. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $3.70 billion, a price-to-earnings ratio of 32.52, a price-to-earnings-growth ratio of 1.44 and a beta of 1.40. Amedisys Inc has a fifty-two week low of $80.13 and a fifty-two week high of $140.91.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.22. The firm had revenue of $467.34 million during the quarter, compared to the consensus estimate of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The firm’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.79 earnings per share. On average, equities analysts anticipate that Amedisys Inc will post 4.08 EPS for the current fiscal year.
A number of brokerages have recently commented on AMED. SunTrust Banks boosted their price objective on Amedisys to $145.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. ValuEngine downgraded Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 14th. Craig Hallum lowered their price objective on Amedisys from $132.00 to $124.00 and set a “hold” rating for the company in a research report on Friday, March 1st. They noted that the move was a valuation call. Finally, Raymond James raised Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price objective for the company in a research report on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Amedisys presently has a consensus rating of “Hold” and a consensus price target of $129.89.
A number of institutional investors and hedge funds have recently made changes to their positions in AMED. Alpha Quant Advisors LLC boosted its holdings in Amedisys by 137.0% in the first quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after purchasing an additional 137 shares in the last quarter. Advantage Investment Management LLC acquired a new position in Amedisys in the first quarter valued at approximately $48,000. Financial Gravity Companies Inc. acquired a new position in Amedisys in the fourth quarter valued at approximately $50,000. Captrust Financial Advisors boosted its holdings in Amedisys by 161.8% in the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock valued at $70,000 after purchasing an additional 369 shares in the last quarter. Finally, Group One Trading L.P. acquired a new position in Amedisys in the fourth quarter valued at approximately $90,000. 86.30% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Amedisys Inc (NASDAQ:AMED) CFO Sells 4,872 Shares of Stock” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2019/06/12/insider-selling-amedisys-inc-nasdaqamed-cfo-sells-4872-shares-of-stock.html.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Read More: What is a balanced fund?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.